| scholarly article | Q13442814 |
| P50 | author | Masanori Ochi | Q90674629 |
| P2093 | author name string | Shinji Hirai | |
| Akinori Yanaka | |||
| Toshiro Kamoshida | |||
| Nobushige Kakinoki | |||
| Atsushi Ohkawara | |||
| Haruka Ohkawara | |||
| P2860 | cites work | Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples | Q24569561 |
| Management of hepatocellular carcinoma: An update | Q27860530 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Hepatocellular carcinoma | Q29616359 | ||
| Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 | ||
| Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). | Q33416688 | ||
| Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104 | Q33897610 | ||
| Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients | Q34193946 | ||
| Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma | Q34263363 | ||
| Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib | Q35583678 | ||
| Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer | Q37010590 | ||
| Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis | Q37062140 | ||
| Chemotherapeutic agents and the skin: An update | Q37110686 | ||
| Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. | Q37263768 | ||
| Patient adherence and persistence with oral anticancer treatment | Q37369704 | ||
| Modified RECIST (mRECIST) assessment for hepatocellular carcinoma | Q37696396 | ||
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 | ||
| On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. | Q38933901 | ||
| Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials | Q41708999 | ||
| Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. | Q43102333 | ||
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial | Q43522867 | ||
| Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 | ||
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial | Q44089673 | ||
| Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. | Q44242768 | ||
| Cutaneous side effects of sorafenib and sunitinib | Q46701138 | ||
| Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis | Q48166586 | ||
| Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. | Q50474760 | ||
| Analysis of survival by tumor response. | Q52874285 | ||
| Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. | Q53097045 | ||
| Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. | Q54526554 | ||
| Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy | Q58811082 | ||
| Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy | Q83465806 | ||
| Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib | Q83791839 | ||
| Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice | Q84115386 | ||
| P433 | issue | 28 | |
| P304 | page(s) | 3155-3162 | |
| P577 | publication date | 2018-07-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib | |
| P478 | volume | 24 |
| Q99565256 | Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib | cites work | P2860 |
Search more.